Haematologica, Vol 92, Issue 1, 110-114 doi:10.3324/haematol.10095
Copyright © 2007 by Ferrata Storti Foundation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Abdalla, A. O.
Right arrow Articles by Österborg, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Abdalla, A. O.
Right arrow Articles by Österborg, A.

Multiple Myeloma

Idiotype protein vaccination in combination with adjuvant cytokines in patients with multiple myeloma - evaluation of T-cell responses by different read-out systems

Amir Osman Abdalla, Lotta Hansson, Ingrid Eriksson, Barbro Näsman-Glaser, Eva D. Rossmann, Hodjattallah Rabbani, Håkan Mellstedt, Anders Österborg

From the Immune and Gene Therapy Laboratory, Cancer Centre Karolinska, Stockholm, Sweden (AOA, LH, IE, HR, HM, AO); Departments of Hematology and Oncology, Karolinska University Hospital Solna (LH, EDR, HM, AO); Department of Oncology/Pathology, Karolinska Institutet, Solna, Stockholm, Sweden (AOA, LH, IE, BN-G, HR, HM, AO)

Correspondence: Håkan Mellstedt, MD, Ph.D., Professor, Department of Oncology, Karolinska University Hospital Solna, SE-171 76, Stockholm, Sweden. E-mail: hakan.mellstedt{at}karolinska.se

Anti-idiotypic T cells were analyzed in myeloma patients (n=18) vaccinated with idiotypic protein together with the adjuvant cytokines granulocyte-macrophage colony-stimulating factor (GM-CSF) and/or interleukin-12 (IL-12). In the group given IL-12/GM-CSF, 78% developed idiotype specific T cells as compared to 22% in the group given only IL-12 (proliferation/ELISPOT assays) (p<0.05). The percentage of immune-responding patients increased when quantitative real time polymerase chain reaction assays for cytokines were included. A predominance of a Th1 (IFN-{gamma}/TNF-{alpha}) immune response was noted in the IL-12 group while a Th2 (IL-5) response prevailed in the IL-12/GM-CSF group (p = 0.053). Application of multiple read-out systems improved the characterization of the immune response.

Key words: idiotype, vaccination, myeloma, T-cell response.




This article has been cited by other articles:


Home page
 Ann OncolHome page
A. O. Abdalla, P. Kokhaei, L. Hansson, H. Mellstedt, and A. Osterborg
Idiotype vaccination in patients with myeloma reduced circulating myeloma cells (CMC)
Ann. Onc., June 1, 2008; 19(6): 1172 - 1179.
[Abstract] [Full Text] [PDF]